Citius Oncology (NASDAQ:CTOR) Stock Price Up 9% – Time to Buy?

Citius Oncology, Inc. (NASDAQ:CTOR)’s stock price shot up 9% on Friday . The stock traded as high as $0.92 and last traded at $0.8779. 184,627 shares changed hands during trading, an increase of 1% from the average session volume of 182,982 shares. The stock had previously closed at $0.8052.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Citius Oncology in a report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.00.

Citius Oncology Price Performance

The company has a quick ratio of 0.32, a current ratio of 0.83 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average price of $0.88 and a two-hundred day moving average price of $1.18. The stock has a market capitalization of $77.50 million, a P/E ratio of -2.83 and a beta of 3.42.

Citius Oncology (NASDAQ:CTOR) last issued its quarterly earnings results on Friday, February 13th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $3.94 million for the quarter, compared to the consensus estimate of $4.37 million.

Institutional Investors Weigh In On Citius Oncology

Several large investors have recently bought and sold shares of CTOR. Citadel Advisors LLC bought a new stake in Citius Oncology in the 3rd quarter worth about $36,000. Bank of America Corp DE increased its holdings in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after buying an additional 8,411 shares in the last quarter. IFP Advisors Inc increased its holdings in Citius Oncology by 49.5% in the 3rd quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock worth $67,000 after buying an additional 11,000 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new stake in Citius Oncology in the 4th quarter worth about $104,000. Finally, Geode Capital Management LLC increased its holdings in Citius Oncology by 31.6% in the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock worth $220,000 after buying an additional 52,875 shares in the last quarter. 70.52% of the stock is currently owned by institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.